Yair Herishanu

Tel Aviv Sourasky Medical Center — Israel

Medicine · Health Sciences

20h-index2.6kcitations70works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(39), Lymphoma Diagnosis and Treatment(19), Cancer Immunotherapy and Biomarkers(6), Immunodeficiency and Autoimmune Disorders(6), Advanced Breast Cancer Therapies(6)

Publications69 total

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma
Blood·2025Open Access
Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL
Blood Advances·2025Open Access
Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.
Journal of Clinical Oncology·2025· 1 cited
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
Blood·2025· 9 citedOpen Access
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.
Journal of Clinical Oncology·2024· 2 cited
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
EClinicalMedicine·2023· 16 citedOpen Access
S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
HemaSphere·2023Open Access
COVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel
HemaSphere·2023· 1 citedOpen Access
Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
2022· 1 citedOpen Access
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
Blood·2022Open Access
Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
Blood·2022
The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
Blood·2022· 1 citedOpen Access
Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Blood·2022Open Access
P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
HemaSphere·2022Open Access
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Journal of Hematology & Oncology·2022· 9 citedOpen Access
Spatial organization and early signaling of the B-cell receptor in CLL
Frontiers in Immunology·2022· 2 citedOpen Access
CLL and COVID-19: light at the end of the tunnel?
Blood·2022· 4 citedOpen Access
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.
Journal of Clinical Oncology·2022· 26 cited
Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
Journal of Clinical Oncology·2022· 5 cited
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL
Research Square (Research Square)·2022Open Access
page 1 of 4Next →

Frequent Co-authors

Chava Perry(14), Adrian Wiestner(9), Irit Avivi(9), Aaron Polliack(8), Ndegwa Njuguna(7), Tamar Tadmor(7), Federica Gibellini(6), Lydia Scarfò(6), Paolo Ghia(6), Andrei Braester(5), Yotam Bronstein(5), Bérengère Vire(4), Wyndham H. Wilson(4), Lev Shvidel(4), Osnat Bairey(4), Gilad Itchaki(4), Najib Dally(4), Ben‐Zion Katz(4), Thomas Chatzikonstantinou(4), Arnon P. Kater(4)